Activist investor Bluebell takes stake in GSK
Reuters
Published Sep 22, 2021 17:32
Updated Sep 22, 2021 18:07
(Reuters) -Activist investor Bluebell Capital Partners has taken a stake worth about 10 million euros in British pharmaceuticals group GlaxoSmithKline in efforts to shake up top management, a Financial Times report https://www.ft.com/content/539c077d-6ac2-4e79-9e0f-8080a31c5530 said on Wednesday.
Bluebell said in a letter to GSK Chairman Jonathan Symonds that chief executive Emma Walmsley should reapply for her job as she would have “renewed credibility both internally and externally”, the FT report said.
Earlier this year, activist Elliott had also taken a stake in GSK, calling for a leadership change at the company. Bluebell was largely backing Elliott's demands, the FT said.
GSK confirmed Bluebell had made demands in a letter.
"We continue to engage extensively with our shareholders with over 500 meetings so far this year," GSK said in a statement.
"They have expressed widespread and strong support for our plans to deliver a step-change in growth and performance, and given clear direction to focus on execution," the company added.
The British pharma major, with a market value of over 71 billion pounds ($96.95 billion), in July rejected Elliott's demands to change its board and sell its consumer healthcare arm.
GSK has set out plans to turn its consumer healthcare arm into a separately listed company, in a move that will deliver an 8 billion pound windfall and other financial benefits to boost drug development at its underperforming pharma business.
Bluebell was part of a successful investor campaign to oust Danone chairman and chief executive Emmanuel Faber in March.
($1 = 0.7323 pounds)
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.